|click to enlarge|
- no NGS testing (neither NCD nor LCD) or
- alternatively can get LCD testing if the test is a "non-targeted-therapy test" (e.g. minimal residual disease tests), and this difference:
- depending on a sentence on page 4 about the scope of the NCD.
The LCD pathway is not specific for indication, though it is specific for advanced cancer and 1 use of a test.
The green boxes show the route to guaranteed NCD coverage: NGS technology & patient has advanced cancer & test is FDA companion diagnostic & patient's cancer is on-label for test & patient has not had this test for this cancer before.
For my long article on implications of the NCD, see here.